Friday - February 13, 2026

Fragile X Syndrome Market to Grow at ~7% CAGR Through 2034 Across 7MM, with 122,000 Diagnosed Cases in 2023 and US Accounting for 58% of Disease Burden | DelveInsight

Fragile X Syndrome Market Leading companies in the Fragile X syndrome space include Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Nova Mentis Life Science, and others. Leading companies in the Fragile X syndrome space include Zynerba Pharmaceuticals, Confluence … Continue reading